Revolade Tablet

Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia lasting 6 months or longer from

Revolade Indications: Thrombocytopenic purpura, severe aplastic anemia in patients with insufficient response to immunosuppressive therapy Class

revolade Revolade Active substance Eltrombopag Holder Novartis Status Closed Indication patients aged 1 year and above with primary immune thrombocytopenia

revolade Initial dose regimen: Adults: Revolade should be initiated at a dose of 25 mg once daily For chronic HCV patients of East-Southeast-Asian ancestry, Revolade